Carmichael Hill & Associates’s Unity Biotechnology UBX Stock Holding History

Carmichael Hill & Associates’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$147	Hold	100	–	–	﹤0.01%	764
2024 Q2	$135	Hold	100	–	–	﹤0.01%	767
2024 Q1	$164	Hold	100	–	–	﹤0.01%	751
2023 Q4	$193	Hold	100	–	–	﹤0.01%	776
2023 Q3	$240	Hold	100	–	–	﹤0.01%	769
2023 Q2	$255	Hold	100	–	–	﹤0.01%	768
2023 Q1	$163	Hold	100	–	–	﹤0.01%	765
2022 Q4	$274	Hold	100	–	–	﹤0.01%	761
2022 Q3	$0	Hold	100	–	–	﹤0.01%	870
2022 Q2	$1K	Hold	100	–	–	﹤0.01%	794
2022 Q1	$1K	Hold	100	–	–	﹤0.01%	783
2021 Q4	$1K	Hold	100	–	–	﹤0.01%	793
2021 Q3	$3K	Hold	100	–	–	﹤0.01%	735
2021 Q2	$5K	Hold	100	–	–	﹤0.01%	679
2021 Q1	$6K	Hold	100	–	–	﹤0.01%	642
2020 Q4	$5K	Buy	+100	New	+$4.82K	﹤0.01%	637

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

Carmichael Hill & Associates's UBX Position: Q3 2024 in Review

Carmichael Hill & Associates held its Unity Biotechnology (UBX) position steady in Q3 2024 at 100 shares worth $147. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Carmichael Hill & Associates first reported a position in UBX in Q4 2020 and has held it in 16 quarters since. The position peaked at $6K in Q1 2021. 38 funds tracked by Wall St. Rank hold UBX as of Q3 2024.

Carmichael Hill & Associates held 100 shares of Unity Biotechnology worth $147 as of Q3 2024.
Carmichael Hill & Associates left its Unity Biotechnology share count unchanged in Q3 2024.
Unity Biotechnology made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #764 holding.
Carmichael Hill & Associates first reported a position in Unity Biotechnology in Q4 2020 and has held it in 16 quarters since.
Carmichael Hill & Associates's Unity Biotechnology position peaked at $6K in Q1 2021.
38 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.